Celon Pharma has reported that its application for co-financing for the project “clinical development of an innovative CPL110 inhibitor in FGFR-dependent tumours”, submitted as part of a competition announced by the Medical Research Agency, has been qualified for co-financing in the amount of PLN19.3m. The total cost of the project is ca. PLN39.8m and its completion date is 31 December 2027. Celon Pharma emphasises that the indicated therapeutic area is of paramount importance as cancer is still the second leading cause of death in Poland. According to the company, despite the continuous development of medicine and targeted cancer therapies, there is still a huge unmet therapeutic need in this area.  (ICE VARSAVIA)

Fonte notizia: bankier.pl